Clinical Trial Update: A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas [Phase 1]

View source ↗

Summary

This Phase I trial evaluated the combination of vorinostat and bortezomib in pediatric patients with refractory or recurrent solid tumors, including central ner…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Tumors
• Lymphoma
• Neuroblastoma
• Sarcoma
• Wilms Tumor

Drugs mentioned

• Velcade (bortezomib)
• Zolinza (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lymphoma, Sarcoma | Phase 1 | Status: COMPLETED